Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy and safety of two different formulations of insulin degludec (IDeg) in subjects with type 2 diabetes.

Timeline

Start

2011-06

Primary completion

2012-01

Completion

2012-01

Outcome

Met primary endpoint

paper A1C reduction with IDeg 200 U/mL was noninferior to that of IDeg 100 U/mL PMID 24518180 ↗

Publications

• Results Bode BW, Chaykin LB, Sussman AM, Warren ML, Niemeyer M, Rabol R, Rodbard HW. Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare). Endocr Pract. 2014 Aug;20(8):785-91. doi: 10.4158/EP13411.OR.

Drugs

Indications